Choi et al. discovered that the therapeutic benefits of fingolimod on autoimmune encephalomyelitis (an animal model of MS) were absent in mice lacking S1PR1 expression in astrocytes, indicating that astrocytes play a crucial role in mediating the effects of fingolimod in MS (Choi et al., 2011). Here, S1PR1 is linked to myeloid sarcoma.